Related Experiment Video
Updated: Feb 20, 2026
Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
Murine breast cancer mastectomy model that predicts patient outcomes for drug development
Eriko Katsuta1, Omar M Rashid2, Kazuaki Takabe3
1Breast Surgery, Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Background:
Despite massive expenditures in preclinical studies, many breast cancer agents show efficacy in murine models but fail in human trials. In humans, metastatic disease determines survival, but preclinical murine models only evaluate drug efficacy against the primary tumor. We hypothesized that evaluating efficacy against metastatic breast cancer would more efficiently predict efficacy in a murine model than evaluating the primary tumor alone. This study (1) critically evaluated a murine tumor removal model with metastatic tumor burden quantification for breast cancer preclinical trials and (2) validated the model with an agent that previously passed preclinical trials but failed human trials.
Materials And Methods:
Tumorectomy and Halsted (radical) mastectomy procedures after inoculation of 4T1-luc2 cells were compared. The effect of AZD0530, an oral Src inhibitor that passed preclinical trials but failed human trials, was evaluated using an inoculation model with/without Halsted mastectomy.
Results:
Significant amounts of residual disease were confirmed by bioluminescence (P = 0.003) and 100% developed local recurrence after tumorectomy versus 14% (P = 0.005) after Halsted mastectomy. Bioluminescence value at 15 min after luciferin injection highly correlated with peak except for 24 h after injection. AZD0530 significantly suppressed primary tumor burden compared with no treatment (P = 0.002); but not in lung metastases. In a Halsted mastectomy model, AZD0530 had no efficacy against lung metastases or difference in survival.
Conclusions:
We critically evaluated and established a murine mastectomy model to evaluate metastatic tumors. It provides a new model for preclinical drug development that mimics the human adjuvant setting.
Insights
Evaluating breast cancer drug efficacy in a new murine model that includes metastatic tumor burden is more predictive of human trial outcomes than traditional primary tumor models. This approach better mimics the human adjuvant setting for preclinical drug development.
Area of Science:
- Oncology
- Translational Research
- Preclinical Models
Background:
- Many breast cancer drugs effective in mouse models fail in human trials.
- Current preclinical models primarily assess efficacy against primary tumors, not metastatic disease, which dictates human survival.
- A novel hypothesis suggests evaluating efficacy against metastatic breast cancer in murine models will better predict human outcomes.
Purpose of the Study:
- To critically evaluate a murine tumor removal model with metastatic tumor burden quantification for breast cancer preclinical trials.
- To validate this model using an agent (AZD0530) that previously succeeded in preclinical studies but failed in human trials.
Main Methods:
- Comparison of tumorectomy and Halsted (radical) mastectomy in mice inoculated with 4T1-luc2 cells.
- Evaluation of the oral Src inhibitor AZD0530's efficacy in a model with and without Halsted mastectomy.
- Quantification of metastatic tumor burden using bioluminescence.
Main Results:
- Tumorectomy resulted in 100% local recurrence, while Halsted mastectomy had 14% recurrence (P<.005).
- AZD0530 suppressed primary tumor burden but showed no efficacy against lung metastases or improved survival in the Halsted mastectomy model.
- Bioluminescence measurements effectively quantified residual disease and correlated with tumor burden.
Conclusions:
- A murine mastectomy model was established and validated for evaluating metastatic tumors.
- This model offers a more predictive preclinical approach for breast cancer drug development.
- The model effectively mimics the human adjuvant setting, improving the translation of preclinical findings to clinical efficacy.
